Candid Therapeutics Inc. has entered into an agreement with Wuxi Biologics Co. Ltd. under which Candid will have exclusive global rights to a preclinical trispecific T-cell engager discovered by Wuxi’s universal multispecific antibody platform, Wuxibody.